Hone Health care bundling strategy

This is the core economic move that turns Hone from a single condition clinic into a recurring care bundle. A patient already doing regular blood work and physician follow ups for testosterone is much easier to sell a second therapy to, like GLP-1s, metformin, or longevity injectables, because the clinical workflow, subscription habit, and trust are already in place. That raises monthly spend and extends retention without starting customer acquisition from zero.

• Hone already had unusually strong lifetime value because testosterone care is sticky, with ongoing dose tuning, lab monitoring, and monthly subscription revenue. New therapies stack onto that same care loop, so one patient can move from a $129 to $149 consult plan plus testosterone into a broader multi product relationship.
  2 sacra
• The newer lines are not random add ons, they map to adjacent needs in the same customer base. Men on testosterone are natural candidates for weight loss and longevity products, while the women’s menopause line uses the same hormone monitoring playbook and has helped drive Hone from $69.7M ARR at the end of 2024 to $113.5M by September 2025.
  1 sacra 3 sacra
• This is also where Hone differs from higher volume telehealth players like Hims, Ro, and Noom. Those businesses often add new categories through lighter prescription workflows, while Hone can bundle medications with blood draws, lab review, quarterly consults, and now in home services from ivee, which makes higher value cross sell easier and supports better margins.
  1 sacra 2 sacra 4 sacra

The next step is for Hone to keep increasing revenue per patient by building a fuller longitudinal care stack around hormones, weight, and wellness. If execution holds, the company can look less like a testosterone seller and more like a specialized digital clinic where each new treatment deepens the patient relationship instead of replacing the last one.